Skip to main navigation

Overview
News & Events
- Press Releases
- Events and Presentations
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Financials
Governance
IR Resources
- Email Alerts
- Contact IR

Press Releases

Press Releases

Recent Releases

September 6, 2022

Athira Pharma Provides Update on Plans for Ongoing LIFT-AD Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients

August 15, 2022

Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates

August 3, 2022

Athira Pharma Presents Data from ACT-AD Phase 2 Proof-of-Concept Clinical Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Patients at the Alzheimer's Association International Conference 2022

Press Releases

Year

January 31, 2022

Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors

January 25, 2022

Athira Pharma Announces Initiation of Patient Dosing in SHAPE, a Phase 2 Clinical Trial of ATH-1017 for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies

January 5, 2022

Athira Pharma Provides 2022 Pipeline Outlook

November 10, 2021

Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update

November 10, 2021

Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference

November 8, 2021

Athira Pharma to Present at Upcoming Investor Conferences

October 29, 2021

Athira Pharma to Host Educational Webinar on the Clinical Applications of ERP P300

October 22, 2021

Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease

October 21, 2021

Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer

September 29, 2021

Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Next page
Last page

Displaying 31 - 40 of 81

SIGN UP FOR EMAIL ALERTS

CONTACT IR

Athira Pharma, Inc.
18706 North Creek Parkway
Suite 104
Bothell, WA 98011

Main line: (866) 725-0930
Local number: (425) 620-8501
info@athira.com

© Athira Pharma, Inc. All rights reserved.